Sarah Raevens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8526877/publications.pdf

Version: 2024-02-01

516710 552781 27 749 16 26 h-index citations g-index papers 27 27 27 1219 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Angiopoietinâ€2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 1087-1104.	7.3	82
2	Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver International, 2015, 35, 1646-1660.	3.9	81
3	Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool. Cellular Immunology, 2017, 322, 74-83.	3.0	81
4	Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: An analysis of cutoff values. Liver Transplantation, 2013, 19, 602-610.	2.4	71
5	Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation. European Journal of Gastroenterology and Hepatology, 2013, 25, 495-502.	1.6	46
6	Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in miceâ€. Hepatology, 2018, 68, 634-651.	7.3	39
7	Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure. Oncotarget, 2015, 6, 28011-28025.	1.8	36
8	Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models. Hepatology, 2018, 68, 2016-2028.	7.3	33
9	Vasomodulators and Liver Transplantation for Portopulmonary Hypertension: Evidence From a Systematic Review and Metaâ€Analysis. Hepatology, 2020, 72, 1701-1716.	7.3	27
10	Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma. BMC Cancer, 2016, 16, 9.	2.6	26
11	Combination of tauroursodeoxycholic acid and Nâ€acetylcysteine exceeds standard treatment for acetaminophen intoxication. Liver International, 2017, 37, 748-756.	3.9	24
12	Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis. International Journal of Molecular Sciences, 2017, 18, 214.	4.1	24
13	Role of angiogenic factors/cell adhesion markers in serum of cirrhotic patients with hepatopulmonary syndrome. Liver International, 2015, 35, 1499-1507.	3.9	23
14	Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. Oncotarget, 2016, 7, 34988-35000.	1.8	22
15	Combination of sivelestat and N-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury. Journal of Leukocyte Biology, 2020, 107, 341-355.	3.3	21
16	Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. Metabolism: Clinical and Experimental, 2020, 107, 154220.	3.4	19
17	Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience. European Respiratory Journal, 2019, 53, 1801096.	6.7	16
18	Diagnosis of Hepatopulmonary Syndrome in a Large Integrated Health System. Clinical Gastroenterology and Hepatology, 2021, 19, 2370-2378.	4.4	13

SARAH RAEVENS

#	Article	IF	CITATIONS
19	Hepatopulmonary syndrome. JHEP Reports, 2022, 4, 100527.	4.9	13
20	Refractory subacute steatohepatitis after biliopancreatic diversion. Hepatology, 2017, 66, 289-291.	7.3	12
21	Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. Digestive and Liver Disease, 2015, 47, 877-883.	0.9	10
22	Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome. Hepatology, 2021, 74, 1674-1686.	7.3	10
23	Metallothioneins alter macrophage phenotype and represent novel therapeutic targets for acetaminophen-induced liver injury. Journal of Leukocyte Biology, 2021, 111, 123-133.	3.3	8
24	Why Pulse Oximetry Is Inaccurate in Liver Cirrhosis: Ancient Knowledge. Hepatology, 2019, 69, 462-463.	7.3	7
25	PORTICO: First Randomized Controlled Trial of Vasomodulator Therapy in Portopulmonary Hypertension. Hepatology, 2020, 71, 1870-1872.	7.3	3
26	Liver Transplantation in Portopulmonary Hypertension: Another Piece of the Puzzle?. Liver Transplantation, 2021, 27, 1709-1710.	2.4	2
27	Response to â€The role of macroaggregated albumin lung perfusion scan in hepatopulmonary syndrome: are we ready to draw conclusions?'. Liver International, 2015, 35, 1919-1920.	3.9	O